Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Interest & Investment Income of $5.2 million for Q1 2026, down 39.5% year-over-year from $8.6 million in Q1 2025, and down 19.63% quarter-over-quarter from $6.5 million in Q4 2025.
Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Interest & Investment Income for 11 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 39.5% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $25.8 million (down 41.07% YoY), while the FY2025 annual figure was $29.2 million, down 38.93% from the prior year.
- Interest & Investment Income slipped to $5.2 million in Q1 2026 per NTLA's latest filing, from $6.5 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $12.7 million in Q3 2023 and bottomed at $540000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $8.3 million across 5 years, with a median of $8.6 million in 2025.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 2118.52% — and 2025, when it sank 44.61%.
- Intellia Therapeutics' Interest & Investment Income stood at $5.4 million in 2022, then soared by 132.7% to $12.5 million in 2023, then fell by 14.67% to $10.6 million in 2024, then tumbled by 39.08% to $6.5 million in 2025, then declined by 19.63% to $5.2 million in 2026.
- Business Quant data shows NTLA's Interest & Investment Income at $5.2 million in Q1 2026, $6.5 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 6.48 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 7.40 Mn |
| Mar 31, 2025 | 8.60 Mn |
| Dec 31, 2024 | 10.63 Mn |
| Sep 30, 2024 | 12.12 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 12.63 Mn |
| Dec 31, 2023 | 12.46 Mn |
| Sep 30, 2023 | 12.74 Mn |
| Jun 30, 2023 | 12.65 Mn |
| Mar 31, 2023 | 11.98 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 703,000.00 |
| Mar 31, 2022 | 540,000.00 |
| Dec 31, 2021 | 503,000.00 |
| Sep 30, 2021 | 349,000.00 |